(HRTX)

Reporting relationship: EVP, Chief Development Officer
Issuer ticker: HRTX
Reported as of: 30 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 10:00:05 UTC
Prior SEC filing: 20 Jan 2026
Next SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathryn Lester Attorney-in-fact for William P. Forbes

Key filing fact

William P. Forbes filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 03 Feb 2026.

Key facts

This page summarizes William P. Forbes's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Feb 2026, 10:00.

Change

Previous filing in this sequence was filed on 20 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001314760 Primary reporting owner

Forbes William P

Relationship: EVP, Chief Development Officer
Address: 100 REGENCY FOREST DRIVE, SUITE 300, CARY
Signature: /s/ Kathryn Lester Attorney-in-fact for William P. Forbes
Signature date: 03 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HRTX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +188,315
Change %
Price: $0.000000
Shares after: 188,315
Date: 30 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 188,315
Exercise price
Footnotes: F1, F2

HRTX transaction Derivative

Performance Stock Units

Award

Transaction value: $0
Shares: +188,314
Change %
Price: $0.000000
Shares after: 188,314
Date: 30 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 188,314
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Footnote F2

On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.

Footnote F3

Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

Footnote F4

On January 30, 2026, the Reporting Person was granted 188,314 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.